MaxCyte, Inc.
MXCTNASDAQHealthcare● Active
$1.17
+$0.03(+2.19%)
Market Cap$124796748
P/E Ratio—
52W High$2.4
52W Low$0.643
MaxCyte, Inc. (MXCT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MXCT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.04
Est. -$0.10 · +60.0%
Revenue
$0.01B
Est. $0.01B · +32.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 2-Quarter EPS Beat Streak
MXCT reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.10 | — | — | — | $0.01B | — |
| ▲ Q2 FY2026 | May 12, 2026 | -$0.10 | -$0.04 | +60.0% | $0.01B | $0.01B | +32.5% |
| ▲ Q1 FY2026 | Mar 24, 2026 | -$0.08 | -$0.06 | +25.0% | $0.01B | $0.01B | -19.6% |
| ▼ Q4 FY2025 | Nov 12, 2025 | -$0.11 | -$0.12 | -9.1% | $0.01B | $0.01B | -27.4% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -$0.10 | -$0.12 | -20.0% | $0.01B | $0.01B | -17.9% |
| — Q2 FY2025 | May 7, 2025 | -$0.10 | -$0.10 | +0.0% | $0.01B | $0.01B | +8.6% |
| ▲ Q1 FY2025 | Mar 11, 2025 | -$0.12 | -$0.10 | +16.7% | $0.01B | $0.01B | -6.2% |
| ▲ Q4 FY2024 | Nov 6, 2024 | -$0.13 | -$0.11 | +15.4% | $0.01B | $0.01B | +6.5% |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.10
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Beat
EPS Actual
-$0.04
EPS Est.
-$0.10
EPS Surpr.
+60.0%
Revenue
$0.01B
Q1 FY2026
Mar 24, 2026Beat
EPS Actual
-$0.06
EPS Est.
-$0.08
EPS Surpr.
+25.0%
Revenue
$0.01B
Q4 FY2025
Nov 12, 2025Miss
EPS Actual
-$0.12
EPS Est.
-$0.11
EPS Surpr.
-9.1%
Revenue
$0.01B
Q3 FY2025
Aug 6, 2025Miss
EPS Actual
-$0.12
EPS Est.
-$0.10
EPS Surpr.
-20.0%
Revenue
$0.01B
Q2 FY2025
May 7, 2025
EPS Actual
-$0.10
EPS Est.
-$0.10
EPS Surpr.
+0.0%
Revenue
$0.01B
Q1 FY2025
Mar 11, 2025Beat
EPS Actual
-$0.10
EPS Est.
-$0.12
EPS Surpr.
+16.7%
Revenue
$0.01B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
-$0.11
EPS Est.
-$0.13
EPS Surpr.
+15.4%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.06 | $-0.06 | $-0.05 | 1 |
| Q3 FY2027 | $-0.07 | $-0.07 | $-0.06 | 1 |
| Q2 FY2027 | $-0.08 | $-0.07 | $-0.07 | 1 |
| Q1 FY2027 | $-0.08 | $-0.07 | $-0.07 | 1 |
| Q4 FY2026 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q3 FY2026 | $-0.07 | $-0.07 | $-0.07 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 12, 2026 | +60.0% | $0.82 | $0.82 | +0.65% |
| ▲ Q1 FY2026 | Mar 24, 2026 | +25.0% | $0.76 | $0.74 | -2.23% |
| ▼ Q4 FY2025 | Nov 12, 2025 | -9.1% | $1.55 | $1.58 | +1.94% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -20.0% | $2.06 | $2.04 | -0.97% |
| ▲ Q2 FY2025 | May 7, 2025 | +0.0% | $2.66 | $2.74 | +3.01% |
| ▲ Q1 FY2025 | Mar 11, 2025 | +16.7% | $3.42 | $3.47 | +1.46% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +15.4% | $3.86 | $3.88 | +0.52% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +35.7% | $4.34 | $4.45 | +2.53% |
Q2 FY2026+0.65%
Report Date
May 12, 2026
EPS Beat/Miss
+60.0%
Price Before
$0.82
Price After
$0.82
Q1 FY2026-2.23%
Report Date
Mar 24, 2026
EPS Beat/Miss
+25.0%
Price Before
$0.76
Price After
$0.74
Q4 FY2025+1.94%
Report Date
Nov 12, 2025
EPS Beat/Miss
-9.1%
Price Before
$1.55
Price After
$1.58
Q3 FY2025-0.97%
Report Date
Aug 6, 2025
EPS Beat/Miss
-20.0%
Price Before
$2.06
Price After
$2.04
Q2 FY2025+3.01%
Report Date
May 7, 2025
EPS Beat/Miss
+0.0%
Price Before
$2.66
Price After
$2.74
Q1 FY2025+1.46%
Report Date
Mar 11, 2025
EPS Beat/Miss
+16.7%
Price Before
$3.42
Price After
$3.47
Q4 FY2024+0.52%
Report Date
Nov 6, 2024
EPS Beat/Miss
+15.4%
Price Before
$3.86
Price After
$3.88
Q3 FY2024+2.53%
Report Date
Aug 6, 2024
EPS Beat/Miss
+35.7%
Price Before
$4.34
Price After
$4.45
Avg Beat Reaction+0.99%
Avg Miss Reaction+0.48%
Beat Rate6 / 8 quarters
Largest Move+3.01% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MXCT ends December
MaxCyte, Inc. (MXCT) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.04 — beating the analyst consensus of $-0.10 by +60.0%. MXCT has beaten EPS estimates for 2 consecutive quarters. The next MXCT earnings date is expected around September 1, 2026.
Each quarter, investors track MXCT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MXCT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MXCT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MXCT earnings · 5 questionsMaxCyte, Inc.'s next earnings report is expected around September 1, 2026. MXCT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MXCT historically reports after market close (AMC).
MXCT earnings datewhen is MXCT earningsMXCT next earnings datewhen does MXCT report earningsMXCT earnings calendar
▸ Source: FMP · MaxCyte, Inc. SEC filings · US GAAP · MaxCyte, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026